# SAFETY DATA SHEET



# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

of the mixture

DARAPRIM TABLETS

Registration number

DARAPRIM TABLETS 25 MG \* DARAPRIM COMPRIMES \* DARAPRIM COMPRIMIDOS \* **Synonyms** 

DARAPRIM TABLETAS \* DARAPRIM TABLETKI \* DARAPRIM TABLETTEN \* NDC NO

0173-0201-55 \* PYRIMETHAMINE, FORMULATED PRODUCT

Issue date 21-November-2014

Version number

21-November-2014 **Revision date** 

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

### 1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

### **SECTION 2: Hazards identification**

### 2.1. Classification of the substance or mixture

### Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

### Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

# 2.2. Label elements

#### Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards Caution - Potent pharmaceutical agent. See section 11 for additional information on health

hazards.

## **SECTION 3: Composition/information on ingredients**

#### 3.2. Mixtures

Material name: DARAPRIM TABLETS SDS MALTA Chemical name % CAS-No. / EC No. REACH Registration No. INDEX No. Notes

PYRIMETHAMINE <= 20 58-14-0 -

200-364-2

**Classification: DSD:** Muta. Cat. 2;R46, Repr. Cat. 2;R60-61, Xn;R22, N;R51/53

**CLP:** Acute Tox. 4;H302, Muta. 1B;H340, Repr. 1B;H360, STOT RE 1;H372,

Aquatic Chronic 2;H411

Starch < 15 9005-25-8 -

232-679-6

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE < 1 557-04-0 -

209-150-3

Classification: DSD: -

CLP: -

Other components below reportable levels > 68

#### List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008. DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance. PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

**Composition comments** The full text for all R- and H-phrases is displayed in section 16.

### **SECTION 4: First aid measures**

General information In the case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

**Skin contact** Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

**Ingestion**If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

4.2. Most important symptoms and effects, both acute and

delayed

Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash, hives, itching) gastrointestinal distress, nausea, vomiting, convulsions, respiratory depression,

decrease in blood pressure.

4.3. Indication of any immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information centre.

# **SECTION 5: Firefighting measures**

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

media

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

None known.

110547 Version #: 08 Revision date: 21-November-2014 Issue date: 21-November-2014

5.2. Special hazards arising from the substance or mixture

During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Material name: DARAPRIM TABLETS

Special fire fighting procedures

Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

### **SECTION 6: Accidental release measures**

### 6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency

personnel

Keep unnecessary personnel away. Wear appropriate protective equipment and clothing during clean-up. Avoid inhalation of dust from the spilled material. Wear a dust mask if dust is generated above exposure limits. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the

SDS.

6.2. Environmental precautions

6.3. Methods and material for containment and cleaning up Avoid discharge into drains, water courses or onto the ground. If sweeping of a contaminated area is necessary use a dust suppressant agent which does not

react with the product. Collect dust using a vacuum cleaner equipped with HEPA filter. Minimise

dust generation and accumulation. Following product recovery, flush area with water.

6.4. Reference to other

sections

For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

## **SECTION 7: Handling and storage**

7.1. Precautions for safe

handling

Provide appropriate exhaust ventilation at places where dust is formed. Minimise dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes. Practice good housekeeping.

7.2. Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store in a well-ventilated place. Store away from

incompatible materials (see Section 10 of the SDS).

Medicinal Product. 7.3. Specific end use(s)

## **SECTION 8: Exposure controls/personal protection**

### 8.1. Control parameters

### Occupational exposure limits

| Components                     | Туре     | Value    | Note                |
|--------------------------------|----------|----------|---------------------|
| PYRIMETHAMINE (CAS<br>58-14-0) | 8 HR TWA | 7 mcg/m3 |                     |
|                                | OHC      | 4        | Reproductive hazard |

**Biological limit values** 

No biological exposure limits noted for the ingredient(s).

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived no-effect level (DNEL)

Predicted no effect concentrations (PNECs) Not available. Not available.

**Exposure guidelines** 

8.2. Exposure controls

Appropriate engineering controls

General ventilation normally adequate. An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the

outcome of a site- or operation-specific risk assessment. Individual protection measures, such as personal protective equipment

**General information** 

Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection

If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166). Not normally

needed.

Skin protection

- Hand protection

For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time). Not

normally needed.

- Other

Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for

splashes, EN ISO 13982 for dust). Not normally needed.

Respiratory protection

When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. No personal respiratory protective equipment normally required.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

Material name: DARAPRIM TABLETS 110547 Version #: 08 Revision date: 21-November-2014 Issue date: 21-November-2014

SDS MALTA

### Hygiene measures

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.

### **Environmental exposure controls**

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

### **SECTION 9: Physical and chemical properties**

### 9.1. Information on basic physical and chemical properties

**Appearance** 

Solid **Physical state** Tablet. Form Colour Not available. Not available. Odour **Odour threshold** Not available. Not available. pН Melting point/freezing point Not available. Not available. Initial boiling point and boiling

range

Not available. Flash point **Evaporation rate** Not available. Not available. Flammability (solid, gas) Upper/lower flammability or explosive limits Not available.

Flammability limit - lower

Flammability limit - upper

(%)

Not available.

Not available. Vapour pressure Vapour density Not available. Not available. Relative density

Solubility(ies)

Solubility (water) Not available. Not available. Solubility (other) Not available.

**Partition coefficient** (n-octanol/water)

Oxidizing properties

**Auto-ignition temperature** Not available. **Decomposition temperature** Not available. Not available. **Viscosity** Not available. **Explosive properties** 

9.2. Other information No relevant additional information available.

Not available.

## **SECTION 10: Stability and reactivity**

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials. Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

10.5. Incompatible materials Acids. Peroxides. Phenols.

None known. Irritating and/or toxic fumes and gases may be emitted upon the product's 10.6. Hazardous

decomposition. decomposition products

# **SECTION 11: Toxicological information**

**General information** Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Material name: DARAPRIM TABLETS 110547 Version #: 08 Revision date: 21-November-2014 Issue date: 21-November-2014 Skin contactHealth injuries are not known or expected under normal use.Eye contactHealth injuries are not known or expected under normal use.IngestionHealth injuries are not known or expected under normal use.

Symptoms Accidental exposure or contact might produce: symptoms of hypersensitivity (such as skin rash,

hives, itching) gastrointestinal distress, nausea, vomiting, convulsions, respiratory depression,

decrease in blood pressure.

11.1. Information on toxicological effects

Acute toxicity May be harmful if swallowed.

Components Species Test results

MAGNESIUM STEARATE (CAS 557-04-0)

**Acute** Oral

LD50 Rat > 2000 mg/kg

PYRIMETHAMINE (CAS 58-14-0)

Acute Oral

LD50 Rat 440 mg/kg

\* Estimates for product may be based on additional component data not shown.

**Skin corrosion/irritation** Health injuries are not known or expected under normal use.

**Irritation Corrosion - Skin** 

PYRIMETHAMINE Acute dermal irritation; OECD 404

Result: Minimal irritant

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE 0

Serious eye damage/eye Direct contact with eyes may cause temporary irritation. Health injuries are not known or expected

irritation under normal use.

Eye

PYRIMETHAMINE Acute ocular irritation; OECD 405

Result: Mild IRE Assay

Result: Negative; not likely to be a severe irritant

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory sensitisation No studies have been conducted.

**Skin sensitisation** Knowledge about sensitisation hazard is incomplete.

**Germ cell mutagenicity** Health injuries are not known or expected under normal use. May cause genetic defects.

Mutagenicity

PYRIMETHAMINE Ames Assay, GLP assay

Result: negative

Chromosomal Aberration Assay In Vitro

Result: positive GreenScreen Assay Result: positive In vivo Micronucleus Result: positive

Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay

Result: positive

SAR, DEREK, Lhasa, UK

Result: Plausible structural alert identified

Sister Chromatid Exchange

Result: positive

**Carcinogenicity** Carcinogenic effects are not expected as a result of occupational exposure.

PYRIMETHAMINE 18 month bioassay

Result: negative Species: Mouse 18 month bioassay Result: negative Species: Rat

25 mg/kg Intraperitoneal

Result: positive Species: Mouse

Material name: DARAPRIM TABLETS

### IARC Monographs. Overall Evaluation of Carcinogenicity

PYRIMETHAMINE (CAS 58-14-0)

3 Not classifiable as to carcinogenicity to humans.

**Reproductive toxicity**Components in this product have been shown to cause birth defects and reproductive disorders in

laboratory animals. Possible risk of harm to the unborn child. May cause harm to breastfed babies.

Reproductivity

PYRIMETHAMINE SAR / QSAR, DEREK, Lhasa, UK

Result: Plausable

Teratogenicity, Literature data

Result: Adverse developmental effects; oral doses of 1-2

mg/kg/day Species: Rat

Specific target organ toxicity -

Not assigned.

single exposure

Specific target organ toxicity - repeated exposure

May cause damage to organs.

PYRIMETHAMINE

Clinical use

Organ: bone marrow; blood; central nevous system

Toet reculte

Aspiration hazard

Not available.

Mixture versus substance

Other information

No information available.

Spacias

information

Components

Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause

adverse effects.

# **SECTION 12: Ecological information**

**12.1. Toxicity** Not expected to be harmful to aquatic organisms.

| Components           |                | Species                                     | lest results                   |  |
|----------------------|----------------|---|--------------------------------|--|
| MAGNESIUM STEARATE   | (CAS 557-04-0) |   |                                |  |
| Aquatic              |                |   |                                |  |
| Acute                |                |   |                                |  |
| Fish                 | EC50           | Orange-red killfish (Adult Oryzias latipes) | 130 mg/l, 96 hours             |  |
| PYRIMETHAMINE (CAS 5 | 58-14-0)       |   |                                |  |
| Acute                |                |   |                                |  |
|                      | IC50           | Activated sludge                            | > 3200 mg/l, 3 hours Nominal   |  |
|                      | NOEC           | Activated sludge                            | 10, 3 hours                    |  |
| Aquatic              |                |   |                                |  |
| Acute                |                |   |                                |  |
| Algae                | EC50           | Green algae (Chlorella pyrenoidosa)         | 20 mg/l, 48 hours              |  |
| Crustacea            | EC50           | Water flea (Daphnia magna)                  | 4.8 mg/l, 48 hours Static test |  |
| Fish                 | EC50           | Rainbow trout (Juvenile Oncorhyncus mykiss) | 5.9 mg/l, 48 hours Static test |  |

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

# 12.2. Persistence and

degradability

**Photolysis** 

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

**Hydrolysis** 

Half-life (Hydrolysis-neutral)

PYRIMETHAMINE 6 Months Measured, Deionized Water

**Biodegradability** 

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

PYRIMETHAMINE 2 %, 28 days Modified MITI (II) Test., Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Material name: DARAPRIM TABLETS

12.3. Bioaccumulative potential

Partition coefficient

n-octanol/water (log Kow)

**PYRIMETHAMINE** 2,7 (Measured).

Bioconcentration factor (BCF)

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

**MAGNESIUM STEARATE** 5.86 Estimated

Mobility in general

Volatility

Henry's law

**PYRIMETHAMINE** 0 atm m^3/mol, 25 C Estimated

Distribution

Octanol/water distribution coefficient log DOW

**PYRIMETHAMINE** 2,44, pH 7,4 Not available.

12.5. Results of PBT

and vPvB assessment

Not available. 12.6. Other adverse effects

### **SECTION 13: Disposal considerations**

#### 13.1. Waste treatment methods

Dispose of in accordance with local regulations. Empty containers or liners may retain some Residual waste

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

The Waste code should be assigned in discussion between the user, the producer and the waste EU waste code

disposal company.

Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not Disposal methods/information

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Dispose in accordance with all applicable regulations. Special precautions

### **SECTION 14: Transport information**

## **ADR**

Not regulated as dangerous goods.

Not regulated as dangerous goods.

**IMDG** 

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

# **SECTION 15: Regulatory information**

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### **EU regulations**

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Material name: DARAPRIM TABLETS 110547 Version #: 08 Revision date: 21-November-2014 Issue date: 21-November-2014 Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

#### **Authorisations**

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

#### Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

## Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations 15.2. Chemical safety Follow national regulation for work with chemical agents. No Chemical Safety Assessment has been carried out.

assessment

### **SECTION 16: Other information**

**List of abbreviations** Not available.

**References** GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any statements or R-phrases and H-statements

under Sections 2 to 15 R2

R22 Harmful if swallowed.

R46 May cause heritable genetic damage. R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R60 May impair fertility.

R61 May cause harm to the unborn child.

H302 Harmful if swallowed. H340 May cause genetic defects.

H360 May damage fertility or the unborn child.

H372 Causes damage to organs through prolonged or repeated exposure.

H411 Toxic to aquatic life with long lasting effects.

**Revision information** Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Physical & Chemical Properties: Toxicological Information: Ecological Information: Mobility

Transport information:

Regulatory Information: United States

**GHS: Classification** 

**Training information** Follow training instructions when handling this material.

Material name: DARAPRIM TABLETS

SDS MALTA

### Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Material name: DARAPRIM TABLETS

110547 Version #: 08 Revision date: 21-November-2014 Issue date: 21-November-2014